The antineoplastic agent docetaxel is synergistic with the Mcl-1 inhibitor S63845 in TNBC and HER2-amplified breast cancers (32), the first-generation pan Bcl-2 family inhibitor ABT-737 in ER+ breast cancer (33), and the Bcl-xL–specific inhibitor A-1331852 in a wide range of solid tumor types (46). This evidence concerns the gene ERBB2 and breast carcinoma.